[Form 4] Verona Pharma plc Insider Trading Activity
Kathleen A. Rickard, Chief Medical Officer and officer of Verona Pharma plc (VRNA), reported a disposition on 08/29/2025 of 189,600 ADSs by Code G (gift) at a price of $0. The filing clarifies that the reported securities are American Depositary Shares (ADSs), each representing eight Ordinary Shares. Following the reported transaction she beneficially owned 2,417,872 Ordinary Shares, comprised of 647,480 Ordinary Shares underlying restricted share units and 1,770,392 Ordinary Shares underlying ADSs. The Form 4 was signed by an attorney-in-fact on her behalf on 09/03/2025.
Il 29/08/2025 Kathleen A. Rickard, Chief Medical Officer e dirigente di Verona Pharma plc (VRNA), ha effettuato una cessione di 189.600 ADS classificata come Codice G (donazione) a un prezzo di $0. La comunicazione specifica che i titoli segnalati sono American Depositary Shares (ADS), ciascuno rappresentante otto Azioni Ordinarie. Dopo l鈥檕perazione ella deteneva beneficiariamente 2.417.872 Azioni Ordinarie, composte da 647.480 Azioni Ordinarie sottostanti unit脿 azionarie vincolate e 1.770.392 Azioni Ordinarie rappresentate da ADS. Il Modulo 4 猫 stato firmato per delega da un procuratore il 03/09/2025.
El 29/08/2025 Kathleen A. Rickard, directora m茅dica y ejecutiva de Verona Pharma plc (VRNA), realiz贸 una disposici贸n de 189.600 ADS bajo el C贸digo G (donaci贸n) a un precio de $0. El informe aclara que los valores son American Depositary Shares (ADS), cada uno representando ocho acciones ordinarias. Tras la operaci贸n, pose铆a beneficiariamente 2.417.872 acciones ordinarias, compuestas por 647.480 acciones ordinarias subyacentes a unidades restringidas y 1.770.392 acciones ordinarias subyacentes a ADS. El Formulario 4 fue firmado por un apoderado en su nombre el 03/09/2025.
2025雲� 8鞗� 29鞚�, Verona Pharma plc (VRNA)鞚� 斓滉碃鞚橅暀毂呾瀯鞛愳澊鞛� 鞛勳洂鞚� Kathleen A. Rickard電� 旖旊摐 G(歃濎棳)搿� 189,600 ADS毳� 雼皜 $0搿� 觳橂秳頄堨姷雼堧嫟. 靹滊電� 氤搓碃霅� 歃濌秾鞚� American Depositary Shares(ADS)鞚措┌, 臧� ADS臧� 8 氤错喌欤�毳� 雮橅儉雮鸽嫟瓿� 氇呾嫓頃╇媹雼�. 頃措嫻 瓯半灅 頉� 攴鸽厐電� 2,417,872 氤错喌欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞙茧┌, 鞚措姅 鞝滍暅攵�欤检嫕雼渼鞐� 旮办磮頃� 647,480 氤错喌欤�鞕� ADS鞐� 旮办磮頃� 1,770,392 氤错喌欤�搿� 甑劚霅╇媹雼�. Form 4電� 2025雲� 9鞗� 3鞚� 攴鸽厐毳� 雽�鞁犿暣 鞙勳瀯雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Le 29/08/2025, Kathleen A. Rickard, Directrice M茅dicale et dirigeante de Verona Pharma plc (VRNA), a d茅clar茅 une cession de 189鈥�600 ADS class茅e Code G (cadeau) au prix de 0 $. Le d茅p么t pr茅cise que les titres d茅clar茅s sont des American Depositary Shares (ADS), chacun repr茅sentant huit actions ordinaires. Suite 脿 l鈥檕p茅ration, elle d茅tenait 脿 titre b茅n茅ficiaire 2鈥�417鈥�872 actions ordinaires, compos茅es de 647鈥�480 actions ordinaires sous-jacentes 脿 des unit茅s d鈥檃ctions restreintes et de 1鈥�770鈥�392 actions ordinaires sous-jacentes 脿 des ADS. Le Formulaire 4 a 茅t茅 sign茅 en son nom par un mandataire le 03/09/2025.
Am 29.08.2025 meldete Kathleen A. Rickard, Chief Medical Officer und leitende Angestellte von Verona Pharma plc (VRNA), eine Verf眉gung 眉ber 189.600 ADS nach Code G (Schenkung) zu einem Preis von $0. Die Einreichung stellt klar, dass es sich bei den gemeldeten Wertpapieren um American Depositary Shares (ADS) handelt, von denen jede acht Stammaktien repr盲sentiert. Nach der gemeldeten Transaktion hielt sie wirtschaftlich 2.417.872 Stammaktien, bestehend aus 647.480 Stammaktien, die zugrunde liegenden Restricted Share Units, und 1.770.392 Stammaktien, die ADS zugrunde liegen. Das Formular 4 wurde am 03.09.2025 in ihrem Namen von einem Bevollm盲chtigten unterzeichnet.
- Retained substantial ownership: Reporting person still beneficially owns 2,417,872 Ordinary Shares after the transaction
- Transaction coded as a gift (Code G): indicates a transfer rather than a market sale, so no proceeds were received
- Material disposition: 189,600 ADSs were disposed of, which represents a meaningful transfer of ADS-level holdings
- Limited disclosure on recipient or purpose: Form does not state who received the gifted ADSs or the reason for the transfer
Insights
TL;DR: An officer reported a charitable or transfer gift of 189,600 ADSs; ownership remains material at over 2.4 million Ordinary Shares.
The filing documents a Code G transaction, which denotes a gift or transfer rather than a market sale, removing cash proceeds from the insider action but changing beneficial ownership. The report specifies ADS mechanics (1 ADS = 8 Ordinary Shares) and provides a post-transaction ownership tally with restricted share units included. For governance review, the timing, recipient, and any related-party details would be relevant but are not disclosed here.
TL;DR: Insider disposition was a non-sale transfer of 189,600 ADSs; holder still maintains a significant position.
From a capital-structure perspective, the report confirms a transfer of ADSs at no cash price and reconfirms the insider retains over 2.4 million Ordinary Shares when counting RSUs and ADS-converted shares. This reduces her direct ADS holdings by the disclosed amount but leaves substantial residual exposure to Verona Pharma equity. The filing lacks information on recipient, purpose, or any trading plan.
Il 29/08/2025 Kathleen A. Rickard, Chief Medical Officer e dirigente di Verona Pharma plc (VRNA), ha effettuato una cessione di 189.600 ADS classificata come Codice G (donazione) a un prezzo di $0. La comunicazione specifica che i titoli segnalati sono American Depositary Shares (ADS), ciascuno rappresentante otto Azioni Ordinarie. Dopo l鈥檕perazione ella deteneva beneficiariamente 2.417.872 Azioni Ordinarie, composte da 647.480 Azioni Ordinarie sottostanti unit脿 azionarie vincolate e 1.770.392 Azioni Ordinarie rappresentate da ADS. Il Modulo 4 猫 stato firmato per delega da un procuratore il 03/09/2025.
El 29/08/2025 Kathleen A. Rickard, directora m茅dica y ejecutiva de Verona Pharma plc (VRNA), realiz贸 una disposici贸n de 189.600 ADS bajo el C贸digo G (donaci贸n) a un precio de $0. El informe aclara que los valores son American Depositary Shares (ADS), cada uno representando ocho acciones ordinarias. Tras la operaci贸n, pose铆a beneficiariamente 2.417.872 acciones ordinarias, compuestas por 647.480 acciones ordinarias subyacentes a unidades restringidas y 1.770.392 acciones ordinarias subyacentes a ADS. El Formulario 4 fue firmado por un apoderado en su nombre el 03/09/2025.
2025雲� 8鞗� 29鞚�, Verona Pharma plc (VRNA)鞚� 斓滉碃鞚橅暀毂呾瀯鞛愳澊鞛� 鞛勳洂鞚� Kathleen A. Rickard電� 旖旊摐 G(歃濎棳)搿� 189,600 ADS毳� 雼皜 $0搿� 觳橂秳頄堨姷雼堧嫟. 靹滊電� 氤搓碃霅� 歃濌秾鞚� American Depositary Shares(ADS)鞚措┌, 臧� ADS臧� 8 氤错喌欤�毳� 雮橅儉雮鸽嫟瓿� 氇呾嫓頃╇媹雼�. 頃措嫻 瓯半灅 頉� 攴鸽厐電� 2,417,872 氤错喌欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨棃鞙茧┌, 鞚措姅 鞝滍暅攵�欤检嫕雼渼鞐� 旮办磮頃� 647,480 氤错喌欤�鞕� ADS鞐� 旮办磮頃� 1,770,392 氤错喌欤�搿� 甑劚霅╇媹雼�. Form 4電� 2025雲� 9鞗� 3鞚� 攴鸽厐毳� 雽�鞁犿暣 鞙勳瀯雽�毽澑鞚� 靹滊獏頄堨姷雼堧嫟.
Le 29/08/2025, Kathleen A. Rickard, Directrice M茅dicale et dirigeante de Verona Pharma plc (VRNA), a d茅clar茅 une cession de 189鈥�600 ADS class茅e Code G (cadeau) au prix de 0 $. Le d茅p么t pr茅cise que les titres d茅clar茅s sont des American Depositary Shares (ADS), chacun repr茅sentant huit actions ordinaires. Suite 脿 l鈥檕p茅ration, elle d茅tenait 脿 titre b茅n茅ficiaire 2鈥�417鈥�872 actions ordinaires, compos茅es de 647鈥�480 actions ordinaires sous-jacentes 脿 des unit茅s d鈥檃ctions restreintes et de 1鈥�770鈥�392 actions ordinaires sous-jacentes 脿 des ADS. Le Formulaire 4 a 茅t茅 sign茅 en son nom par un mandataire le 03/09/2025.
Am 29.08.2025 meldete Kathleen A. Rickard, Chief Medical Officer und leitende Angestellte von Verona Pharma plc (VRNA), eine Verf眉gung 眉ber 189.600 ADS nach Code G (Schenkung) zu einem Preis von $0. Die Einreichung stellt klar, dass es sich bei den gemeldeten Wertpapieren um American Depositary Shares (ADS) handelt, von denen jede acht Stammaktien repr盲sentiert. Nach der gemeldeten Transaktion hielt sie wirtschaftlich 2.417.872 Stammaktien, bestehend aus 647.480 Stammaktien, die zugrunde liegenden Restricted Share Units, und 1.770.392 Stammaktien, die ADS zugrunde liegen. Das Formular 4 wurde am 03.09.2025 in ihrem Namen von einem Bevollm盲chtigten unterzeichnet.
FAQ
What did Kathleen Rickard report on Form 4 for VRNA?
How many Verona Pharma shares does the reporting person own after the transaction?
What does Code G mean on the Form 4 transaction?
How are ADSs related to Verona Pharma Ordinary Shares in this filing?
Does the Form 4 explain the recipient or purpose of the 189,600 ADS transfer?
